vimarsana.com

Latest Breaking News On - Alto neuroscience - Page 3 : vimarsana.com

Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape - Alto Neuroscience (NYSE:ANRO)

Alto Neuroscience reported positive results for its novel PDE4 inhibitor in a Phase 1 study for cognitive impairment associated with schizophrenia.

William blairAlto neurosciencePrecision psychiatry platformAlto scope

Insiders are Piling into These 10 Healthcare Stocks in 2024

In this article, we will take a detailed look at Insiders are Piling into These 10 Healthcare Stocks in 2024. For a quick overview of such stocks, read our article Insiders are Piling into These 5 .

United statesEli lillyEricw robertsJeffrey scott rileySnehals patelNicholas conrad smithNovo nordiskNumber of hedge fund investorsInstitute global use of medicinesEli lilly and coAlto neuroscience incCenters for medicareOutlook therapeutics incGreenwich lifesciences incCalcimedica incMedicaid services

Alto Neuroscience (ANRO) Commences Phase 2 Study of ALTO-203

Alto Neuroscience (ANRO) Commences Phase 2 Study of ALTO-203
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jessica powellAlto neuroscience incAlto neurosciencePrecision psychiatry platformBond lader visual analog scale

Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder

Phase 2 study designed to evaluate the pharmacodynamic effects, pharmacokinetics, and tolerability of ALTO-203 in patients with major depressive disorder and higher levels of anhedonia ALTO-203.

Jessica powellExchange commissionAlto neuroscience incAlto neurosciencePrecision psychiatry platformBond lader visual analog scalePrivate securities litigation reform actAnnual report

Boundless Bio breaks IPO lull with $100M fundraise

BioPharma

Dive briefArch venture partnersSan diego basedKyverna therapeuticsAlto neuroscienceBiopharma diveVersant ventures backed contineum therapeuticsRenaissance capital

vimarsana © 2020. All Rights Reserved.